Genmab A/S-Product Pipeline Review-2015

Genmab A/S-Product Pipeline Review-2015

  • Products Id :- GMDHC07000CDB
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Genmab A/S-Product Pipeline Review-2015


Global Markets Direct's, 'Genmab A/S-Product Pipeline Review-2015', provides an overview of the Genmab A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genmab A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Genmab A/S including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Genmab A/S's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Genmab A/S's pipeline products

Reasons To Buy

Evaluate Genmab A/S's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Genmab A/S in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Genmab A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Genmab A/S and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genmab A/S

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Genmab A/S and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Genmab A/S Snapshot 6

Genmab A/S Overview 6

Key Information 6

Key Facts 6

Genmab A/S-Research and Development Overview 7

Key Therapeutic Areas 7

Genmab A/S-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products-Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

Genmab A/S-Pipeline Products Glance 16

Genmab A/S-Late Stage Pipeline Products 16

Phase III Products/Combination Treatment Modalities 16

Genmab A/S-Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Genmab A/S-Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Genmab A/S-Drug Profiles 20

ofatumumab 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

teprotumumab 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

HuMax-TF-ADC 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

DuoBody Cancer-5 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

DuoBody Cancer-6 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

EM1-mAb 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Humax Cancer-3 ADC 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

HuMax-AXL-ADC 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

HuMax-TAC-ADC 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

IDD-004 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibodies for Central Nervous System, Infectious Disease, Oncology and Autoimmune Disorders 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Monoclonal Antibody 1 for Central Nervous System Disorders 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibody 2 for Central Nervous System Disorders 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Monoclonal Antibody 3 for Central Nervous System Disorders 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

TF-011 Monomethyl Auristatin E 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Genmab A/S-Pipeline Analysis 40

Genmab A/S-Pipeline Products by Target 40

Genmab A/S-Pipeline Products by Route of Administration 41

Genmab A/S-Pipeline Products by Molecule Type 42

Genmab A/S-Pipeline Products by Mechanism of Action 43

Genmab A/S-Recent Pipeline Updates 44

Genmab A/S-Dormant Projects 49

Genmab A/S-Discontinued Pipeline Products 50

Discontinued Pipeline Product Profiles 50

HuMax-CD74-ADC 50

ofatumumab 50

teprotumumab 50

Genmab A/S-Company Statement 51

Genmab A/S-Locations And Subsidiaries 53

Head Office 53

Other Locations & Subsidiaries 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

Genmab A/S, Key Information 6

Genmab A/S, Key Facts 6

Genmab A/S-Pipeline by Indication, 2015 8

Genmab A/S-Pipeline by Stage of Development, 2015 10

Genmab A/S-Monotherapy Products in Pipeline, 2015 11

Genmab A/S-Partnered Products in Pipeline, 2015 12

Genmab A/S-Partnered Products/ Combination Treatment Modalities, 2015 13

Genmab A/S-Out-Licensed Products in Pipeline, 2015 14

Genmab A/S-Out-Licensed Products/ Combination Treatment Modalities, 2015 15

Genmab A/S-Phase III, 2015 16

Genmab A/S-Phase II, 2015 17

Genmab A/S-Phase I, 2015 18

Genmab A/S-Preclinical, 2015 19

Genmab A/S-Pipeline by Target, 2015 40

Genmab A/S-Pipeline by Route of Administration, 2015 41

Genmab A/S-Pipeline by Molecule Type, 2015 42

Genmab A/S-Pipeline Products by Mechanism of Action, 2015 43

Genmab A/S-Recent Pipeline Updates, 2015 44

Genmab A/S-Dormant Developmental Projects,2015 49

Genmab A/S-Discontinued Pipeline Products, 2015 50

Genmab A/S, Subsidiaries 53

List of Figures

Genmab A/S-Pipeline by Top 10 Indication, 2015 8

Genmab A/S-Pipeline by Stage of Development, 2015 10

Genmab A/S-Monotherapy Products in Pipeline, 2015 11

Genmab A/S-Partnered Products in Pipeline, 2015 12

Genmab A/S-Out-Licensed Products in Pipeline, 2015 14

Genmab A/S-Pipeline by Top 10 Target, 2015 40

Genmab A/S-Pipeline by Top 10 Route of Administration, 2015 41

Genmab A/S-Pipeline by Top 10 Molecule Type, 2015 42

Genmab A/S-Pipeline Products by Top 10 Mechanism of Action, 2015 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Genmab A/S; Genmab A/S - Key Therapeutics; Genmab A/S - Pipeline Overview and Promising Molecules; Genmab A/S - News; Genmab A/S - Latest Updates; Genmab A/S - Pipeline; Genmab A/S - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]